晚期心力衰竭的医疗管理成本:拉丁美洲的观点
Livia Adams Goldraich1,2, Ana Paula Beck da Silva Etges3,4, Laura Caroline Tavares Hastenteufel1,2
1Programa de Insuficiência Cardíaca Avançada e Transplante Cardíaco, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS - Brasil.
Arquivos brasileiros de cardiologia
|December 19, 2025
概括
晚期心力衰竭患者无法获得左心室辅助器件 (LVAD) 的患者面临重大财务负担. 对于这些人来说,持续的医疗管理成本是相当大的.
科学领域:
- 心脏病学 心脏病学
- 卫生经济学 卫生经济学
背景情况:
- 晚期心力衰竭 (HF) 造成了巨大的财务负担.
- 拉丁美洲缺乏关于无法接受心脏移植或左心室辅助器件 (LVAD) 的患者成本的数据.
研究的目的:
- 开展一项针对高级HF患者的微投注研究,这些患者有资格使用LVAD,但无法使用LVAD.
- 描述这种特定患者群体的财务负担.
主要方法:
- 直接医疗保健成本的微成本分析.
- 使用基于时间驱动的基于活动的成本计算方法.
- 来自LVAD的患者级成本分析需要识别到死亡或随访结束.
主要成果:
- 该研究量化了先进的高频管理所带来的财务负担.
- 根据疾病严重程度和死亡率评估了成本变化.
结论:
- 持续的医疗管理的先进的HF患者不符合LVADs承担实质性的财务成本.
- 这些发现支持对精选人群的LVAD等先进疗法的成本效益进行评估.
相关概念视频
Heart Failure V: Medical Management
198
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
198
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Heart Failure VII: Nursing Interventions
396
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
396
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
Rheumatic Heart Disease III: Medical Management
264
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
264
Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313


